September 8, 2021

Antibe Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

 TORONTO, CANADA — (September 8, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, today announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually on September 13 – … Continued

more
August 19, 2021

Antibe Therapeutics Announces Results of 2021 Annual Meeting

TORONTO, CANADA — (August 19, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier today. All resolutions outlined in the management information … Continued

more
August 17, 2021

Antibe Therapeutics Reports Q1 2022 Interim Financial and Operating Results

– Ended quarter with a strong $67 million cash position – AME study on required pause; data expected in October TORONTO, CANADA — (August 17, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, has filed its … Continued

more
August 9, 2021

Antibe Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference

TORONTO, CANADA — (August 9, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, today announced its participation in the Canaccord Genuity 41st Annual Growth Conference being held virtually on August 10 – 12. … Continued

more
August 3, 2021

Antibe Therapeutics Provides Clinical Update for Otenaproxesul

– Current AME study paused in adherence to safety protocol  TORONTO, CANADA — (August 3, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, has placed its absorption, metabolism and excretion (“AME”) study of otenaproxesul on a … Continued

more
July 27, 2021

Antibe Therapeutics Provides July 2021 Corporate Update

– Phase III preparations proceeding well; AME study underway – New IP in development to expand indications and bolster existing pipeline – Potential listing on senior U.S. exchange synchronized with first Phase III trial TORONTO, CANADA – (July 27, 2021) To our shareholders, Our achievements in the last twelve months have set the stage for … Continued

more
June 28, 2021

Antibe Therapeutics Reports 2021 Year-End Results and Business Highlights

– Phase III-enabling activities for otenaproxesul proceeding well; AME study begins next week – Ended year with a strong $72 million cash position, providing over two years of runway and fully funding Phase III adaptive trial  TORONTO, CANADA — (June 28, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging … Continued

more
June 25, 2021

Antibe Therapeutics Collaborates with Dalriada Drug Discovery to Accelerate Pipeline Expansion

– Enables rapid advancement of multiple drug discovery programs to exploit hydrogen sulfide platform in new disease areas TORONTO, CANADA — (June 25, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its unique hydrogen sulfide platform to develop next-generation safer therapies to target inflammation in a wide range of health … Continued

more
June 7, 2021

Antibe Therapeutics to Present at Upcoming Virtual Investor Conferences

TORONTO, CANADA — (June 7, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, today announced its participation in the following U.S.-based virtual investor conferences in June: 2021 LD Micro Invitational XI, Live company … Continued

more
June 3, 2021

Antibe Therapeutics Announces Close of Amalgamation Transaction to Unify Intellectual Property Ownership

 NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES TORONTO, CANADA — (June 3, 2021) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX:ATE) is pleased to announce that, further to its press release dated May 7, 2021, the Company has completed its previously announced amalgamation transaction (the “Transaction”) to … Continued

more
May 7, 2021

Antibe Therapeutics Announces Agreement to Unify Intellectual Property Ownership

– Amalgamation secures 100% ownership of IP underlying Antibe’s pipeline – Strengthens position in large-market partnering discussions  TORONTO, CANADA — (May 7, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) (“Antibe” or the “Company”), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory … Continued

more
March 29, 2021

Antibe Therapeutics Receives FDA Clearance of IND Application for Otenaproxesul for Osteoarthritis

– Enables expansion to U.S.-based clinical trials, advances preparation for Phase III program TORONTO, CANADA — (March 29, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for inflammation arising from a wide range of medical conditions, today announced that the … Continued

more
March 3, 2021

Antibe Therapeutics to Present at Upcoming Virtual Investor Conferences

TORONTO, CANADA — (March 3, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions, today announced its participation in the following investor conferences in March: H.C. Wainwright Global Life … Continued

more
February 24, 2021

Antibe Therapeutics Announces Closing of Bought Deal Public Offering

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES TORONTO — (February 24, 2021) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX:ATE) today announced that it has closed its previously announced bought deal public offering of 6,727,500 units (the “Offered Securities”) in the capital of the Company at a … Continued

more
February 17, 2021

Antibe Therapeutics Announces C$35 Million Bought Deal Public Offering

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES TORONTO, CANADA — (February 17, 2021) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX:ATE) today announced that it has entered into an agreement with Canaccord Genuity Corp. on behalf of a syndicate of underwriters (together, the “Underwriters”) and pursuant to … Continued

more
February 12, 2021

Antibe Therapeutics Reports Q3 2021 Interim Financial and Operating Results

TORONTO, CANADA — (February 12, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today filed its financial and operating results for the fiscal quarter ended December 31, 2020. “We had a busy quarter and made excellent … Continued

more
February 9, 2021

Antibe Therapeutics Announces Strategic Licensing Deal in China with Nuance Pharma

– US$100 million in milestone payments including US$20 million upfront, as well as a double-digit royalty – Nuance’s business model, commercial acumen and collaborative approach considered an ideal fit for Antibe   TORONTO, CANADA — (February 9, 2021) – Antibe Therapeutics Inc. — (TSX: ATE, OTCQB: ATBPF) today announced that it has licensed otenaproxesul to Nuance … Continued

more
January 11, 2021

Antibe Therapeutics Provides 2021 Corporate Update

 – Large market partnering program now underway – – Limited COVID-19 impact: Phase III program slated to start in second half of 2021 – – U.S. institutional outreach expanding –  TORONTO, CANADA — (January 11, 2021) To our shareholders, As we build on last year’s significant clinical and capital markets achievements and enter the homestretch in … Continued

more

archives

Attention

This is an external link. Click “OK” to continue.

CANCEL OK